The Food and Drug Administration has placed a hold on 4D Molecular Therapeutics’ Fabry gene therapy. The company characterized the hold as an “administrative step [that] has no impact on our plans or timing for the 4D-310 program.” (Endpoints News)
Teva Pharmaceuticals has left lobbying group PhRMA. It remains a member of the generic drug lobbying group Association for Accessible Medicines. (STAT)
A majority of Americans support a tobacco ban designed to minimize health issues linked to tobacco products, according to a Centers for Disease Control and Prevention study. “These findings can inform efforts to prohibit all tobacco product sales, including menthol cigarettes, and reduce tobacco use and advance health equity,” the researchers wrote. (Axios)
The FDA has approved Gilead’s breast cancer drug Trodelvy for an advanced form of breast cancer. Gilead expects that the expanded approval will make between 6,000 and 8,000 patients eligible for the drug. (Reuters)
As nursing homes and long-term care facilities face massive caregiver and healthcare worker shortages, some experts are pushing policymakers to create pathways for immigrants to fill the roles. “Immigration policy is a long-term care policy,” said David Grabowski, professor of healthcare policy at Harvard Medical School. (Kaiser Health News)
